Advanced Search

Display
per page
  Report Title Date Provider Type Pgs Price

Mesoblast Ltd: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.

This report is essential reading for any serious investor, providing comprehensive financial information on a company's perfo...

06 Feb 2016 Reuters Investment Profile 12 $20.00

Mesoblast Ltd: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.

This report is essential reading for any serious investor, providing comprehensive financial information on a company's perfo...

06 Feb 2016 Reuters Investment Profile 12 $20.00

Thomson Reuters Stock Report - Mesoblast Ltd (MSB-AU)

StockReports+ gathers Thomson Reuters independent research, ratings and market data into a single report that optimizes the i...

10 Feb 2016 Thomson Reuters Stock Report 11 $25.00

Wright Investors Service Comprehensive Report for Mesoblast Ltd

Quantitative analyses of financial statements (Income Statement, Balance Sheet and Sources of Capital), extensive ratio table...

08 Feb 2016 Wright Reports 55 $75.00

ValuEngine Rating and Forecast Report for MESO

Advanced academic research that brings you superior investment strategies in an actionable format. The most comprehensive and...

07 Feb 2016 ValuEngine, Inc. 11 $25.00

Mesoblast Limited - Appendix 4C - Quarterly Report for Entities Admitted on the Basis of Commitments

28 Jan 2016 irasia.com 5 $58.00

MESOBLAST - UPCOMING LAUNCH ON FIRST PRODUCT APPROVAL

As a leader in stem cell technologies, Mesoblast continues to make good pipeline progress, nearing market readiness for its m...

25 Jan 2016 Edison Investment Research 9 $10.00

Mesoblast Limited (MSB) - Financial Analysis Review

Mesoblast Limited (MSB) - Financial Analysis Review Summary Mesoblast Limited (Mesoblast) is a regenerative medicine company ...

21 Jan 2016 GlobalData 53 $300.00

Mesoblast Limited - Mesoblast - A Global Leader in Cell Based Medicines - CEO's Presentation at JP Morgan Healthcare Conference

14 Jan 2016 irasia.com 32 $368.00

Mesoblast Limited - Phase 3 Heart Failure Trial Size to be Substantially Reduced Following FDA Discussions

11 Jan 2016 irasia.com 2 $23.00